Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial:...

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Intimal hyperplasia is a primary cause of restenosis after coronary stent implantation.
• Enoxaparin has demonstrated inhibitory effects on smooth muscle cell proliferation in preclinical studies.
• Reducing restenosis is crucial for long-term success of coronary stenting.

Purpose of the Study:

• To evaluate the efficacy of intramural enoxaparin delivery in preventing restenosis after stenting de novo coronary lesions.
• To compare local enoxaparin administration with standard systemic heparinization.

Main Methods:

• A prospective randomized trial involving 100 patients undergoing coronary stenting.
• Patients were assigned to either local enoxaparin delivery with reduced systemic heparin or standard systemic heparinization.
• The primary endpoint was late luminal loss, with secondary endpoints including major adverse cardiac events and restenosis at 6 months.

Main Results:

• Local enoxaparin delivery significantly reduced late luminal loss (0.76 mm vs 1.07 mm, P<0.001).
• Restenosis rates were lower in the enoxaparin group (10% vs 24%, P<0.05).
• Target lesion revascularization was also reduced in the enoxaparin group (8% vs 22%, P<0.05).

Conclusions:

• Local intramural delivery of enoxaparin is effective in reducing late luminal loss and restenosis after stenting de novo coronary lesions.
• This represents the first prospective randomized trial demonstrating the benefit of local drug delivery for reducing restenosis post-stenting.
• The findings suggest a novel therapeutic strategy for improving outcomes in interventional cardiology.